Gilead Sciences
Gilead Sciences, Inc. is an American biopharmaceutical company that researches, develops, and commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
History[edit | edit source]
Gilead Sciences was founded in 1987 by Michael L. Riordan, a medical doctor. The company was originally named Oligogen, Inc. and was later renamed Gilead Sciences. Gilead's first product, Vistide (cidofovir), was approved by the U.S. Food and Drug Administration (FDA) in 1996 for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS.
Products[edit | edit source]
Gilead Sciences has developed several notable drugs, including:
- Atripla - a combination drug for the treatment of HIV/AIDS.
- Truvada - used for both treatment and pre-exposure prophylaxis (PrEP) of HIV.
- Harvoni - a combination drug for the treatment of hepatitis C.
- Sovaldi - used for the treatment of hepatitis C.
- Remdesivir - an antiviral drug that has been used in the treatment of COVID-19.
Research and Development[edit | edit source]
Gilead Sciences invests heavily in research and development (R&D) to discover and develop new therapies. The company has a strong focus on antiviral therapies but also explores treatments for other conditions, including oncology and inflammatory diseases.
Acquisitions[edit | edit source]
Gilead has expanded its portfolio through several key acquisitions:
- Pharmasset - acquired in 2011, which brought the hepatitis C drug Sovaldi into Gilead's portfolio.
- Kite Pharma - acquired in 2017, which added CAR-T cell therapy for cancer treatment to Gilead's offerings.
- Immunomedics - acquired in 2020, which added the breast cancer drug Trodelvy to Gilead's portfolio.
Corporate Governance[edit | edit source]
Gilead Sciences is headquartered in Foster City, California. The company's CEO is Daniel O'Day, who took over the role in 2019. The company is publicly traded on the NASDAQ under the ticker symbol GILD.
Controversies[edit | edit source]
Gilead Sciences has faced criticism and legal challenges over the pricing of its drugs, particularly its hepatitis C treatments Sovaldi and Harvoni. The high cost of these drugs has led to debates about drug pricing and access to essential medications.
See also[edit | edit source]
References[edit | edit source]
External links[edit | edit source]
Lua error in mw.title.lua at line 318: bad argument #2 to 'title.new' (unrecognized namespace name 'Portal').
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
